Oramed Pharmaceuticals Inc (ORMP)
2.33
0.00 (0.00%)
USD |
NASDAQ |
Nov 14, 16:00
2.33
0.00 (0.00%)
After-Hours: 20:00
Oramed Pharmaceuticals Enterprise Value: -58.86M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -58.86M |
| November 12, 2024 | -58.25M |
| November 11, 2024 | -59.06M |
| November 08, 2024 | -59.47M |
| November 07, 2024 | -56.62M |
| November 06, 2024 | -58.25M |
| November 05, 2024 | -57.84M |
| November 04, 2024 | -56.21M |
| November 01, 2024 | -59.06M |
| October 31, 2024 | -56.62M |
| October 30, 2024 | -55.39M |
| October 29, 2024 | -60.29M |
| October 28, 2024 | -59.06M |
| October 25, 2024 | -57.23M |
| October 24, 2024 | -57.43M |
| October 23, 2024 | -56.62M |
| October 22, 2024 | -57.03M |
| October 21, 2024 | -58.04M |
| October 18, 2024 | -59.27M |
| October 17, 2024 | -55.80M |
| October 16, 2024 | -54.58M |
| October 15, 2024 | -57.84M |
| October 14, 2024 | -56.62M |
| October 11, 2024 | -56.62M |
| October 10, 2024 | -56.82M |
| Date | Value |
|---|---|
| October 09, 2024 | -55.80M |
| October 08, 2024 | -58.66M |
| October 07, 2024 | -55.39M |
| October 04, 2024 | -57.84M |
| October 03, 2024 | -55.39M |
| October 02, 2024 | -56.21M |
| October 01, 2024 | -55.80M |
| September 30, 2024 | -54.17M |
| September 27, 2024 | -52.54M |
| September 26, 2024 | -55.80M |
| September 25, 2024 | -56.21M |
| September 24, 2024 | -57.84M |
| September 23, 2024 | -58.86M |
| September 20, 2024 | -59.47M |
| September 19, 2024 | -52.95M |
| September 18, 2024 | -54.99M |
| September 17, 2024 | -51.32M |
| September 16, 2024 | -52.54M |
| September 13, 2024 | -52.13M |
| September 12, 2024 | -57.43M |
| September 11, 2024 | -56.62M |
| September 10, 2024 | -55.80M |
| September 09, 2024 | -55.39M |
| September 06, 2024 | -57.84M |
| September 05, 2024 | -59.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-80.02M
Minimum
Jan 26 2023
1.038B
Maximum
Nov 08 2021
112.50M
Average
45.32M
Median
May 13 2020
Enterprise Value Benchmarks
| Skye Bioscience Inc | 92.14M |
| Scilex Holding Co | 194.99M |
| NovaBay Pharmaceuticals Inc | 3.432M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 9.212M |
| Total Expenses (Quarterly) | 3.135M |
| EPS Diluted (Quarterly) | 0.22 |
| Earnings Yield | 21.89% |
| Normalized Earnings Yield | -21.89 |